MAXON
Maxon , the developers of professional software solutions for editors, filmmakers, motion designers and visual effects artists, today announced that all Maxon products are now included in its value-packed subscription: Cinema 4D, Redshift, Red Giant, Universe, Forger and now ZBrush, acquired in December of last year, are all included in Maxon One for the same affordable price. Additionally, Maxon unveiled its Spring 2022 product upgrades that include an incredible set of new features and enhancements. This multi-product, feature-rich update once again illustrates Maxon’s commitment to delivering consistent product development and superior value to the Maxon One offering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220420005268/en/
“Our goal is to provide artists with trailblazing technology and workflows to create in all dimensions,” said David McGavran, Maxon CEO. “This expansive update across all of Maxon’s creative tools comes together to provide incredible value and opportunities for creative expression in Maxon One.”
See Maxon One in Action at NAB 2022 and on The 3D and Motion Design Show
Maxon will be hosting exclusive presentations from industry-leading artists in its Booth (#N5920) at NAB 2022, April 24-27, 2022. For those unable to attend the show, the presentations will be streaming simultaneously at 3DMotionShow.com .
Exciting new enhancements and upgrades to Maxon One products include:
Cinema 4D S26: Significant emphasis has been put on unifying workflows with the best technology from around the Maxon family – the additions of Redshift CPU and ZBrush’s automatic retopology tools. Cinema 4D Subscription Release 26 also includes great enhancements across the entire 3D workflow - Modeling, Animation, Simulation, Rendering.
Redshift: Redshift is Everywhere. With the initial release of Redshift CPU, users can make use of Redshift’s powerful materials and rendering on any system and a growing number of creative tools including Houdini, Maya, 3ds max, Blender, Katana, Vectorworks and Archicad. The new Redshift Standard material is easy to use and offers diverse shading models for improved photorealism.
Red Giant:
- VFX Suite 3 introduces Real Lens Flares based on simulated optical models and ray traced light. This technology preview will evolve with the participation of our artistic community.
- Magic Bullet Suite 16 adds new Halation and Optical Diffusion tools for Looks, along with OpenColorIO support.
- Trapcode Suite 18 now offers M1 support for all Trapcode tools, and layer maps support in Particular.
Universe: Universe 6 adds exciting new tools providing many new options to be creative and enhance an artist’s workflow. Sketchify adds sketch- and toon-like effects to footage, ChromaTown creates chromatic streaks and blurs for warpy looks and transitions, Box Bokeh provides square or diamond shaped lens bokeh effects, and Stretch Transition adds a stretchy crossfade between clips for a warp-like transition. Combined with over 70 new presets, Universe 6 helps artists to get impressive results quickly in a fun and intuitive way.
Forger: The latest version of Forger reveals the first stage in Maxon’s plan to provide powerful hard-surface modeling capabilities to 3D artists. Built with Cinema 4D’s polygonal foundation, Forger now offers a selection of polygonal primitives: planes, cubes, spheres, cylinders, torus, pyramids, capsules, oil tanks, etc.
Maxon One subscribers can immediately download all product updates via Maxon App. Everyone can download a 14-day trial of the entire Maxon One offering from within Maxon App and experience for themselves all the great new features across the entire Maxon family of products.
More Details at maxon.net
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush , the industry-standard digital sculpting and painting solution.
Maxon’s team is comprised of fun, passionate people who believe in building and empowering a successful artistic community. From our popular, inclusive events to our free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to our ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005268/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom